SecBot SecBot
8-K ·Filed Apr 23, 2026

WST

WEST PHARMACEUTICAL SERVICES INC
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0000105770-26-000047
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Monitor the next quarter's revenue and adjusted EPS for continued momentum in high-value products and GLP-1 demand, which are key drivers of the raised guidance.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$307.95
T+0 close · Apr 23, 2026 · via day close
Latest settled
+16.33%
T+60 · $358.24
Vs SPY
+11.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $307.95entry
  2. T+1 · 7mo ago −0.66%α −1.45% · $305.91
  3. T+5 · 7mo ago −4.09%α −5.57% · $295.36
  4. T+20 · 6mo ago −0.80%α −5.43% · $305.50
  5. T+60 · 4mo ago +16.33%α +11.41% · $358.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

West Pharmaceutical Services reported strong Q1 2026 results with revenue of $844.9M (+21.0% YoY) and adjusted EPS of $2.13 (+46.9% YoY), significantly beating consensus. The company raised its full-year 2026 revenue guidance to $3.295B-$3.350B and adjusted EPS guidance to $8.40-$8.75, driven by strong organic growth in high-value products and GLP-1 demand.

Key Financial Metrics

EPS
$2.13
est $1.68 · +26.8%
Revenue
$844.9M
est $779.4M · +8.4% · +21.0% YoY
Rating
strong beat
Guidance
$3.295B-$3.350B
raised
Free Cash Flow
$47.2M
Gross Margin
35.1%

Key Facts

  • Q1 2026 revenue: $844.9M, +21.0% YoY (+15.3% organic)
  • Q1 2026 adjusted EPS: $2.13, +46.9% YoY
  • Raised full-year 2026 revenue guidance to $3.295B-$3.350B (from $3.215B-$3.275B)
  • Raised full-year 2026 adjusted EPS guidance to $8.40-$8.75 (from $7.85-$8.20)
  • Repurchased 1.2M shares for $297.6M during Q1

Financial Impact

$844.9M revenue, $2.13 adjusted EPS

revenueepsguidancebuyback

Risk Factors

  • Currency fluctuations could impact reported revenue growth

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000105770-26-000047
Document: wst-20260423.htm0000105770-26-000047
Document: a1q26earningsdeck-final.htm0000105770-26-000047
Document: 0000105770-26-000047-index-headers.html0000105770-26-000047
Document: 0000105770-26-000047-index.html0000105770-26-000047
Document: 0000105770-26-000047.txt0000105770-26-000047
8-K Data (Synthetic)0000105770-26-000047

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026